[go: up one dir, main page]

IT1264965B1 - Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce - Google Patents

Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Info

Publication number
IT1264965B1
IT1264965B1 IT93MI002412A ITMI932412A IT1264965B1 IT 1264965 B1 IT1264965 B1 IT 1264965B1 IT 93MI002412 A IT93MI002412 A IT 93MI002412A IT MI932412 A ITMI932412 A IT MI932412A IT 1264965 B1 IT1264965 B1 IT 1264965B1
Authority
IT
Italy
Prior art keywords
treatment
bloccanti
alfa
early ejaculation
ejaculation
Prior art date
Application number
IT93MI002412A
Other languages
English (en)
Inventor
Giorgio Cavallini
Original Assignee
Giorgio Cavallini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giorgio Cavallini filed Critical Giorgio Cavallini
Priority to IT93MI002412A priority Critical patent/IT1264965B1/it
Publication of ITMI932412A0 publication Critical patent/ITMI932412A0/it
Priority to JP7513583A priority patent/JPH09504798A/ja
Priority to US08/624,603 priority patent/US5707999A/en
Priority to EP94931582A priority patent/EP0728000A1/en
Priority to PCT/EP1994/003661 priority patent/WO1995013072A1/en
Publication of ITMI932412A1 publication Critical patent/ITMI932412A1/it
Application granted granted Critical
Publication of IT1264965B1 publication Critical patent/IT1264965B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Si descrive l'uso di farmaci ?1-bloccanti nel trattamento della eiaculazione precoce psicogena.
IT93MI002412A 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce IT1264965B1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
JP7513583A JPH09504798A (ja) 1993-11-12 1994-11-08 早発性射精の治療におけるアルフゾシンまたはテラゾシンの使用
US08/624,603 US5707999A (en) 1993-11-12 1994-11-08 Use of alfuzosin or terazosin in the treatment of premature ejaculation
EP94931582A EP0728000A1 (en) 1993-11-12 1994-11-08 The use of alfuzosin or terazosin in the treatment of premature ejaculation
PCT/EP1994/003661 WO1995013072A1 (en) 1993-11-12 1994-11-08 The use of alfuzosin or terazosin in the treatment of premature ejaculation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Publications (3)

Publication Number Publication Date
ITMI932412A0 ITMI932412A0 (it) 1993-11-12
ITMI932412A1 ITMI932412A1 (it) 1995-05-12
IT1264965B1 true IT1264965B1 (it) 1996-10-17

Family

ID=11367195

Family Applications (1)

Application Number Title Priority Date Filing Date
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Country Status (5)

Country Link
US (1) US5707999A (it)
EP (1) EP0728000A1 (it)
JP (1) JPH09504798A (it)
IT (1) IT1264965B1 (it)
WO (1) WO1995013072A1 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037360A (en) * 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
CZ299712B6 (cs) 1999-09-03 2008-10-29 Apbi Holdings, Llc Použití dapoxetinu pro zvládnutí sexuální dysfunkce podáváním zpusobem podle potreby
US6814695B1 (en) 1999-11-11 2004-11-09 Medicare Management Consultancy Limited Apparatus and method to assist in the diagnosis of premature ejaculation
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
WO2002074241A2 (en) 2001-03-16 2002-09-26 Dmi Biosciences Inc. Method of delaying ejaculation
WO2003057223A1 (en) 2002-01-02 2003-07-17 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
CA2643677C (en) * 2005-04-14 2015-06-23 Mount Cook Biosciences, Inc. Compositions of novel opioid compounds and method of use thereof
WO2007070779A2 (en) 2005-12-13 2007-06-21 Trinity Laboratories, Inc. A method to treat premature ejaculation in humans
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence

Also Published As

Publication number Publication date
WO1995013072A1 (en) 1995-05-18
ITMI932412A0 (it) 1993-11-12
EP0728000A1 (en) 1996-08-28
US5707999A (en) 1998-01-13
JPH09504798A (ja) 1997-05-13
ITMI932412A1 (it) 1995-05-12

Similar Documents

Publication Publication Date Title
ES2138247T3 (es) Composicion y uso.
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
GR890100008A (el) Παράγωγα ισοκινολίνης, παρασκευή τους και χρήση τους.
IT1285770B1 (it) Composti corticoidei
ES2157992T3 (es) Alcoxi-alquil-carbamatos de imidazo(1,2-a)piridinas.
GB2380939B (en) Treatment or prevention of auto-immune diseases
IT1251838B (it) Uso della nimesulide nel trattamento della cataratta
ITPD920145A0 (it) Uso terapeutico della fosforil-serina-n-acil-sfingosina
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
ITMI940141A0 (it) Determinazione della tossicita' delle acque mediante l'uso di una batterica anaerobica
ITMI912430A1 (it) Uso di un composto anilino-pirimidinico ad attivita' fungicida nel trattamento della venturia
ITMI930520A1 (it) Procedimento per la preparazione di disperdenti solfonati.
ES2113765T3 (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaespiro(4.5)decano-2-propanamina.
ZA916313B (en) New use of a monoclonal antibody
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
ITMI950729A1 (it) Uso della lisofosfatidilcolina nel campo della riproduzione umana
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
IT1255639B (it) Uso dell'oxatomide come agente antitosse
ITMI912511A0 (it) Uso di formulazioni liposomiali contenenti papaverina nel trattamento della impotenza maschile

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971127